Steven Potts

Doing what I love. Fighting a disease I hate.

[Steven Potts @DesertBiopharma]

@DavidHongMD Two great friends and awesome cancer doctors!

[Steven Potts @DesertBiopharma]

@LifeSciVC @drrichjlaw Great point!

[Steven Potts @DesertBiopharma]

@yaireinhorn @daphnezohar @SeaportTx Talk to your Mass Senator Warren who has consistently been a deliberate headwind against the industry for years. Anti-biotech policies directly lead to elimination of Boston STEM Jobs. This is on your own anti-biotech leaders in MA. Wake them up!

[Steven Potts @DesertBiopharma]

Just because planes have turbulence doesn't mean magic carpets fly. Thanks @Dr_RShatsky

[Nisha Patel, MD MS, Dipl of ABOM, CCMS @DrPlantel]

I’ll say this again, loud, clear, and a thousand times over if I have to: as a doctor working in the system, I know our healthcare system is far from perfect. But its flaws are not an excuse to peddle pseudoscience and grift. And don’t let anyone tell you otherwise.

Sorry, not sorry. 🤷🏽‍♀️

[Steven Potts @DesertBiopharma]

@PeterKolchinsky Nicely done. That was really fun to read. Conversely, I should try having AI build a deck, send an email pitch, schedule a call, walk through the science, and field questions. Ha!

[Steven Potts @DesertBiopharma]

@adamfeuerstein @matthewherper Keep at it Adam. Your reporting was very well done and fair.

[VitalTransformation @VitalTransform]

Patient advocacy groups and disease foundations hold a pivotal role in shaping legislative outcomes.

As Robert Coughlin observed, delivering targeted briefings to legislators can bridge the gap between technical policy proposals and real‑world patient impact. In the context of reconciliation discussions, this approach is essential to securing data exclusivity extensions - extending small‑molecule data protection from nine to 13 years under the EPIC Act – and advancing similar reforms.

In our latest Vital Health Podcast episode, host Duane Schulthess was joined by @BobCoughlin (@JLL) and Steve Potts (@DesertBiopharma, @WarOnCancer) to explore the pill penalty, its effects on venture capital allocation and regional biotech clusters, and the role of coordinated advocacy in sustaining innovation.

Listen to the full discussion here: https://t.co/9K84MK159B

#EPIC #EPICAct #IRA #Pharma #Policy

[Steven Potts @DesertBiopharma]

Sobering reality of the MFN insanity.
https://t.co/9Srbm8Nwtb

[Better Science Better Health @BSBHbyVT]

In an ever-evolving healthcare landscape, understanding how policy shapes innovation becomes increasingly important. Without that understanding - barriers to drug development, such as uneven exclusivity periods, can halt the development of new treatments.

We sat down for a conversation with @DesertBiopharma and @BobCoughlin to explore these challenges.

In our discussion, we unpack how nine-year data exclusivity for small molecules versus 13 years for biologics imposes a “pill penalty” that steers investment away from affordable therapies for older adults. We then explore policy remedies such as the EPIC Act and orphan drug reforms designed to rebalance incentives and improve patient access. Ultimately, we emphasize the essential role of patient advocacy, regional biotech ecosystems, and the necessity of a stable innovation environment to achieve future cures.

Listen now: https://t.co/oI0g6K1DgG

#VitalHealthPodcast #Biotech #Policy #DrugDevelopment #Health #Pharma #Pharmaceuticals #Biotechnology

[VitalTransformation @VitalTransform]

In an ever-evolving healthcare landscape, understanding how policy shapes innovation becomes increasingly important. Without that understanding - barriers to drug development, such as uneven exclusivity periods, can halt the development of new treatments.

We sat down for a conversation with @DesertBiopharma and @BobCoughlin to explore these challenges.

In our discussion, we unpack how nine-year data exclusivity for small molecules versus 13 years for biologics imposes a “pill penalty” that steers investment away from affordable therapies for older adults. We then explore policy remedies such as the EPIC Act and orphan drug reforms designed to rebalance incentives and improve patient access. Ultimately, we emphasize the essential role of patient advocacy, regional biotech ecosystems, and the necessity of a stable innovation environment to achieve future cures.

Listen now: https://t.co/9K84MK159B

#VitalHealthPodcast #Biotech #Policy #DrugDevelopment #Health #Pharma #Pharmaceuticals #Biotechnology

[Steven Potts @DesertBiopharma]

@daphnezohar @IAmBiotech Done. (Ds though)

[Steven Potts @DesertBiopharma]

Too many me-toos?

So tired hearing this lie about our biotech industry - that all we do is me-too drugs. So what I thought would be pretty easy - took me 3 Linkedin posts to cover all the novel MoA drugs in for just one year and one disease (cancer)

https://t.co/z0xbwbTFmh

[Steven Potts @DesertBiopharma]

@DuaneSchulthess @IQVIA_Institute @ASCO Looking forward to it Duane!

[Steven Potts @DesertBiopharma]

@JoanneMeeks5 @BiotechCH These are always the BEST discussions on almost any biotech topic - kudos to everyone who volunteers their time on Biotech Hangout! Thank you!

[Steven Potts @DesertBiopharma]

@BiotechCH It doesn't matter if legislation actually happens, investors respond to the threat of legislating happening. So damage already occurs and has occurred.

[Steven Potts @DesertBiopharma]

50/50 odds fixing the IRA small molecule penalty? In biotech, those are WINNING odds!
We work years of our lives on compounds with a 10% chance in the clinic. Now we have a coin flip to save innovation affecting HALF our industry.
Sign, share this letter:
https://t.co/KBEVnvXqEe

[Steven Potts @DesertBiopharma]

The IRA pill penalty will hurt promising longevity small molecule programs as well. Please sign our patient advocacy letter to help fix this:
https://t.co/KBEVnvXqEe

[Agingdoc🩺Dr David Barzilai🔔MD PhD MS MBA DipABLM @agingdoc1]

I just connected with Steve Potts, CEO of a stealth biotherapeutics making a real impact for patients through advocacy & development of innovative small molecule cancer therapeutics⚕️

Consider supporting this important work:

🔗 https://t.co/nuY9XJ20bQ

🫡 @DesertBiopharma

[Agingdoc🩺Dr David Barzilai🔔MD PhD MS MBA DipABLM @agingdoc1]

I just connected with Steve Potts, CEO of a stealth biotherapeutics making a real impact for patients through advocacy & development of innovative small molecule cancer therapeutics⚕️

Consider supporting this important work:

🔗 https://t.co/nuY9XJ20bQ

🫡 @DesertBiopharma

[VitalTransformation @VitalTransform]

Research, including ours, shows a 70% drop in small-molecule investment after the IRA cut negotiations—risking 188 fewer drugs and 116M lost life-years. The EPIC Act (H.R. 1492) calls for an 11-year negotiation period.

Read more: https://t.co/DQiBfBCwCu

#IRA #Pharma

[Dom Lucre | Breaker of Narratives @dom_lucre]

🔥🚨DEVELOPING: Apple CEO Tim Cook was spotted looking confused when nobody noticed him at a New Orleans restaurant. Cook is estimated to be worth over 2.5 billon yet people walked past him as if he was a local rapper.